How many institutions held PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share in Q2 2024?

7 institutional investors reported PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share for Q2 2024. Use the holders table for investor-level position and value details.

PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI)

Q: What does CUSIP 696389402 represent in this 13F holders report?

CUSIP 696389402 is the security identifier for PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share used to aggregate holder disclosures.

CUSIP: 696389402

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / Common Stock, par value $0.01 per share
Shares outstanding: 159,058,879
Total 13F shares: 30,078
Share change: +30,078
Total reported value: $135,352
Price per share: $4.50
Number of holders: 7
Value change: +$135,352
Number of buys: 7

Quarterly Holders Quick Answers

What is CUSIP 696389402?
CUSIP 696389402 identifies PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024

Recent filing periods for CUSIP 696389402:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Yuma Regional Medical Center	3/4/5	10%+ Owner	— class O/S missing	1,814,375	$925,331	—	19 Aug 2021	3/4/5
ARMISTICE CAPITAL, LLC	13F	Company	— class O/S missing	720,000	$287,352	—	31 Mar 2024	13F
Thomas Hallam	3/4/5	Chief Executive Officer, Director	— mixed-class rows	137,592 mixed-class rows	$29,372	—	16 Aug 2022	3/4/5
VANGUARD GROUP INC	13F	Company	— class O/S missing	68,054	$27,160	—	31 Mar 2024	13F
Marex Group plc	13F	Company	— class O/S missing	35,759	$14,271	—	31 Mar 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	— class O/S missing	34,448	$13,748	—	31 Mar 2024	13F
HRT FINANCIAL LP	13F	Company	— class O/S missing	32,326	$12,000	—	31 Mar 2024	13F
TWO SIGMA SECURITIES, LLC	13F	Company	— class O/S missing	28,208	$11,258	—	31 Mar 2024	13F
STATE STREET CORP	13F	Company	— class O/S missing	22,463	$8,965	—	31 Mar 2024	13F
Michael John Dawson	3/4/5	Chief Medical Officer	— class O/S missing	15,000	$7,650	—	29 Mar 2022	3/4/5
MILLENNIUM MANAGEMENT LLC	13F	Company	— class O/S missing	18,200	$7,264	—	31 Mar 2024	13F
Cristina Csimma	3/4/5	Director	— mixed-class rows	19,742 mixed-class rows	$5,609	—	08 Feb 2024	3/4/5
Stephanie Diaz	3/4/5	Director	— mixed-class rows	19,680 mixed-class rows	$5,582	—	08 Feb 2024	3/4/5
James R. Neal	3/4/5	Director	— mixed-class rows	17,800 mixed-class rows	$4,762	—	09 Feb 2024	3/4/5
Robert J. Trenschel	3/4/5	Director	— mixed-class rows	17,800 mixed-class rows	$4,762	—	08 Feb 2024	3/4/5
Mary Ann Gray	3/4/5	Director	— mixed-class rows	12,700 mixed-class rows	$2,968	—	21 Nov 2023	3/4/5
Robert Curtis McRae	3/4/5	Chief Operating Officer	— mixed-class rows	2,588 mixed-class rows	$1,320	—	03 Apr 2023	3/4/5
UBS Group AG	13F	Company	— class O/S missing	2,225	$887	—	31 Mar 2024	13F
MORGAN STANLEY	13F	Company	— class O/S missing	2,108	$841	—	31 Mar 2024	13F
Federation Des Caisses Desjardins du Quebec	13F	Individual	— class O/S missing	1,500	$599	—	31 Mar 2024	13F
WELLS FARGO & COMPANY/MN	13F	Company	— class O/S missing	411	$164	—	31 Mar 2024	13F
Orion Capital Management LLC	13F	Company	— class O/S missing	299	$119	—	31 Mar 2024	13F
BFSG, LLC	13F	Company	— class O/S missing	40	$16	—	31 Mar 2024	13F
BlackRock Finance, Inc.	13F	Company	— class O/S missing	9	$4	—	31 Mar 2024	13F
FMR LLC	13F	Company	— class O/S missing	3	$1	—	31 Mar 2024	13F

Institutional Holders of PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI) as of Q2 2024

As of 30 Jun 2024, PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI) was held by 7 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 30,078 shares. The largest 8 holders included Marex Group plc, ARMISTICE CAPITAL, LLC, UBS Group AG, Tower Research Capital LLC (TRC), MORGAN STANLEY, Federation des caisses Desjardins du Quebec, WELLS FARGO & COMPANY/MN, and BANK OF AMERICA CORP /DE/. This page lists 8 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q4 2025 Across Filers

Q4 2025 holders

Q2 2024 holders

Holder diff

-80

Investor	Q4 2025 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.